LB Pharmaceuticals Inc (LBRX)
| Market Cap | 1.29B +260.6% |
| Revenue (ttm) | n/a |
| Net Income | -85.69M |
| EPS | -3.81 |
| Shares Out | 32.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,594 |
| Open | 39.80 |
| Previous Close | 39.83 |
| Day's Range | 39.23 - 40.76 |
| 52-Week Range | 14.32 - 50.16 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 58.00 (+44.78%) |
| Est. Earnings | Nov 9, 2026 |
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for LBRX stock is "Strong Buy." The 12-month stock price target is $58.0, which is an increase of 44.78% from the latest price.
News
LB Pharmaceuticals Transcript: R&D Day 2026
NOVA-1 showed efficacy across doses, early improvement and signals in negative symptoms and cognition, alongside low EPS and minimal QTc prolongation. NOVA-2 data are expected H1 2027; bipolar depression and adjunctive MDD readouts are planned for 2028 and 2029.
LB Pharmaceuticals Slides: FY 2026
LB Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 27, 2026.
LB Pharmaceuticals management to meet with Piper Sandler
Meeting to be held in New York on October 29 hosted by Piper Sandler.
LB Pharmaceuticals to Participate in Upcoming Investor Events
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-imp...
LB Pharmaceuticals Slides: Corporate presentation
LB Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 15, 2026.
LB presents preclinical data ‘supporting’ LB-102’s mechanism of action
LB Pharmaceuticals (LBRX) announced the presentation of four posters at the 39th European College of Neuropsychopharmacology Congress, taking place in Munich, Germany from October 10-13, 2026. The pos...
LB Pharmaceuticals initiated with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $65 price target LB is developing novel therapeutics for central nervous system disorders, the a...
LB Pharmaceuticals initiated with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $65 price target
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-imp...
Guggenheim stats LB Pharmaceuticals at Buy, calls best idea
Guggenheim analyst Delma Caiati initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $80 price target The analyst named LB a best idea. LB-102 is a Phase 3…
LB Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $80 price target
LB Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded LB Pharmaceuticals (LBRX) to Neutral from Buy with a price target of $35, down from $37. Faster development and competitive setbacks “strengthen LB-102’s development value, but...
LB Pharmaceuticals initiated with a Buy at Needham
Needham initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $68 price target The company’s LB-102 is an improved version of amisulpride, one of the most effective antipsychotics…
LB Pharmaceuticals files automatic mixed securities shelf
16:09 EDT LB Pharmaceuticals (LBRX) files automatic mixed securities shelf
LB Pharmaceuticals Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
LB-102, a potent amisulpride derivative, shows robust efficacy and a favorable safety profile in schizophrenia, with potential expansion into mood disorders and Alzheimer's-related indications. Phase III data for schizophrenia is expected in the first half of next year.
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-im...
LB Pharmaceuticals to Participate in Upcoming September Investor Events
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-im...
LB Pharmaceuticals appoints Joseph Miller as CFO
LB Pharmaceuticals (LBRX) announced the appointment of Joseph Miller as CFO. Prior to joining LB Pharmaceuticals, Miller served as CFO of Aurinia Pharmaceuticals (AUPH).
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-im...
LB Pharmaceuticals price target raised to $60 from $45 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on LB Pharmaceuticals (LBRX) to $60 from $45 and keeps a Buy rating on the shares post the Q2 report.
LB Pharmaceuticals price target raised to $69 from $45 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on LB Pharmaceuticals (LBRX) to $69 from $45 and keeps a Buy rating on the shares. The firm sees a…
LB Pharmaceuticals price target raised to $54 from $46 at BMO Capital
BMO Capital raised the firm’s price target on LB Pharmaceuticals (LBRX) to $54 from $46 and keeps an Outperform rating on the shares. The company’s earnings report highlights meaningful strides…
LB Pharmaceuticals price target raised to $53 from $40 at Stifel
Stifel raised the firm’s price target on LB Pharmaceuticals (LBRX) to $53 from $40 and keeps a Buy rating on the shares. After having sat down with CEO Heather Turner…
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into ne...
LB Pharmaceuticals Slides: Corporate presentation
LB Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.